GlaxoSmithKline Stock – Innoviva Buys Back GlaxoSmithKline’s Stake for $392 Million
By Chris Wack
Innoviva Inc. said it is buying back GlaxoSmithKline’s equity stake in Innoviva for $392 million.
Innoviva said the 32 million shares, representing 32% of the company’s outstanding common stock, will be bought back at $12.25 a share, a 3% discount to the 5-day volume weighted average price of the company’s common stock.
“We view the buyback as a compelling and highly accretive transaction demonstrating our ability to act strategically and opportunistically at the same time,” Chief Executive Pavel Raifeld said.
Moelis & Company acted as a financial advisor and Willkie Farr Gallagher acted as a legal advisor to Innoviva.
Write to Chris Wack at [email protected] Zoom.com
(END) Dow Jones Newswires